Jieduquyuziyin Prescription Suppresses Inflammatory Activity of MRL/lpr Mice and Their Bone Marrow-Derived Macrophages via Inhibiting Expression of IRAK1-NF-κB Signaling Pathway

Lina Ji, Xuemin Fan, Xiaoli Hou, Danqing Fu, Jie Bao, Zhuang Aiwen, Sixiang Chen, Yongsheng Fan, Rongqun LiFrontiers in Pharmacology 2020 · DOI

TL;DR

This study investigates the traditional Chinese medicine Jieduquyuziyin prescription (JP) for treating Systemic Lupus Erythematosus (SLE). Researchers found that JP effectively suppresses inflammatory activity in MRL/lpr mice and their bone marrow-derived macrophages by inhibiting the IRAK1-NF-κB signaling pathway, offering a potential new therapeutic avenue for SLE.

What Problem Does This Paper Address?

Systemic Lupus Erythematosus (SLE) is a severe autoimmune disease characterized by widespread inflammation and damage to various organs. While conventional treatments exist, they often have limited efficacy and significant side effects. Traditional Chinese Medicine (TCM) formulas, like Jieduquyuziyin prescription (JP), have shown clinical promise in treating SLE, but their underlying molecular mechanisms remain largely unelucidated. Specifically, the role of the IRAK1-NF-κB signaling pathway in SLE pathogenesis and how JP might modulate it has not been thoroughly explored. This paper aims to bridge this knowledge gap by investigating JP's therapeutic effects and its mechanism of action in an established mouse model of SLE.

Methods

The researchers employed a multi-faceted approach combining in vitro and in vivo experiments.

  • Quality Control of JP: High-Performance Liquid Chromatography (HPLC) and Liquid Chromatography-Mass Spectrometry (LC-MS) were used to identify and quantify key active components in JP and JP-treated serum.
  • In Vitro Studies: Bone marrow-derived macrophages (BMDMs) were isolated from MRL/lpr and MRL/MP mice. These cells were then stimulated with Lipopolysaccharide (LPS) and treated with JP-treated serum to assess inflammatory cytokine production (TNF-α, IL-6) and the expression of key proteins in the IRAK1-NF-κB pathway. Cell viability was also assessed using the CCK8 assay.
  • In Vivo Studies: MRL/lpr mice were treated with JP for 8 weeks. The study evaluated renal pathology using Hematoxylin and Eosin (H&E) staining, measured urinary albumin and serum anti-dsDNA levels via ELISA, and analyzed the expression of inflammatory cytokines and IRAK1-NF-κB pathway components in spleen and kidney tissues using quantitative Real-Time Polymerase Chain Reaction (RT-qPCR) and Western Blot analysis.
  • Flow Cytometry: Used to confirm the purity of isolated BMDMs.

Datasets

Not discussed in the paper.

Key Insights and Ideas

  • JP's Broad Anti-inflammatory Action: JP demonstrated significant anti-inflammatory effects not only in isolated macrophages but also in the complex biological system of lupus-prone mice, impacting multiple organs.
  • Targeting the IRAK1-NF-κB Axis: The study strongly implicates the IRAK1-NF-κB signaling pathway as a key mediator of JP's therapeutic effects in SLE. This pathway is a critical regulator of inflammatory responses, and its suppression by JP offers a specific mechanistic explanation for its efficacy.
  • Dual In Vitro and In Vivo Validation: The findings from in vitro studies on BMDMs were consistently mirrored by the in vivo results in MRL/lpr mice, strengthening the evidence for JP's mechanism of action.
  • Potential for Kidney Protection: The observed alleviation of renal pathological damage, reduced urinary protein, and decreased anti-dsDNA levels highlight JP's potential to protect against a common and severe complication of SLE.

Key Results

  • Reduced Cytokine Secretion: In LPS-stimulated BMDMs from MRL/lpr mice, JP treatment significantly reduced the secretion of pro-inflammatory cytokines IL-6 and TNF-α.
  • Inhibition of IRAK1-NF-κB Pathway: JP treatment led to decreased expression of IRAK1 and its downstream NF-κB pathway components in both in vitro (BMDMs) and in vivo (spleen and kidney) settings.
  • Improved Renal Pathology: MRL/lpr mice treated with JP showed reduced glomerular swelling, mesangial cell proliferation, and inflammatory cell infiltration in their kidneys compared to the model group.
  • Decreased Biomarkers of Disease: JP treatment significantly reduced urinary albumin and serum anti-dsDNA levels in MRL/lpr mice.
  • Differential Effects: JP's effects were more pronounced in MRL/lpr mice (which develop a more severe lupus phenotype) compared to MRL/MP mice.

Limitations and Future Work

  • Complexity of JP: JP is a complex prescription with multiple active ingredients. While paeoniflorin and ferulic acid were identified as key components, further research is needed to pinpoint the exact contribution of each ingredient and their synergistic effects.
  • Precise Mechanism of IRAK1-NF-κB Inhibition: While the study demonstrates JP's ability to suppress the IRAK1-NF-κB pathway, the precise molecular interactions and upstream/downstream targets require further investigation.
  • Clinical Translation: While promising, these findings are based on animal models. Future work should focus on translating these findings into human clinical trials to confirm JP's safety and efficacy in SLE patients. The authors suggest that further elucidation of JP's mechanism of action is valuable for its clinical application.

Summary updated

Abstract

Jieduquyuziyin prescription (JP) has been used to treat systemic lupus erythematosus (SLE). Although the effectiveness of JP in the treatment of SLE has been clinically proven, the underlying mechanisms have yet to be completely understood. We observed the therapeutic actions of JP in MRL/lpr mice and their bone marrow-derived macrophages (BMDMs) and the potential mechanism of their inhibition of inflammatory activity. To estimate the effect of JP on suppressing inflammatory activity, BMDMs of MRL/lpr and MRL/MP mice were treated with JP-treated serum, and MRL/lpr mice were treated by JP for 8 weeks. Among them, JP and its treated serum were subjected to quality control, and BMDMs were separated and identified. The results showed that in the JP group of BMDMs stimulated by Lipopolysaccharide (LPS) in MRL/lpr mice, the secretion of interleukin-6 (IL-6) and tumor necrosis factor-α (TNF-α) reduced, and the expressions of Interleukin-1 receptor-associated kinase 1 (IRAK1) and its downstream nuclear factor κB (NF-κB) pathway decreased. Meanwhile, the alleviation of renal pathological damage, the decrease of urinary protein and serum anti-dsDNA contents, the inhibition of TNF-α level, and then the suppression of the IRAK1-NF-κB inflammatory signaling in the spleen and kidney, confirmed that the therapeutic effect of JP. These results demonstrated that JP could inhibit the inflammatory activity of MRL/lpr mice and their BMDMs by suppressing the activation of IRAK1-NF-κB signaling and was supposed to be a good choice for the treatment of SLE.
BibTeX
@inproceedings{ji2020jieduquyuziyin,
  author = {Lina Ji and Xuemin Fan and Xiaoli Hou and Danqing Fu and Jie Bao and Zhuang Aiwen and Sixiang Chen and Yongsheng Fan and Rongqun Li},
  title = {{Jieduquyuziyin Prescription Suppresses Inflammatory Activity of MRL/lpr Mice and Their Bone Marrow-Derived Macrophages via Inhibiting Expression of IRAK1-NF-κB Signaling Pathway}},
  booktitle = {Frontiers in Pharmacology},
  year = {2020},
  doi = {10.3389/fphar.2020.01049},
}
Figure